Research programme: human placental growth factor - ThromboGenics

Drug Profile

Research programme: human placental growth factor - ThromboGenics

Latest Information Update: 28 Mar 2008

Price : $50

At a glance

  • Originator University of Leuven
  • Developer ThromboGenics
  • Class Growth factors
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Ischaemic heart disorders; Peripheral arterial occlusive disorders; Wounds

Most Recent Events

  • 28 Mar 2008 Preclinical development is ongoing
  • 18 Jan 2007 Preclinical trials in Wounds in Europe (unspecified route)
  • 08 Mar 2004 Preclinical trials in Peripheral arterial occlusive disorders in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top